| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1997PNAS...94.4686K |
| P356 | DOI | 10.1073/PNAS.94.9.4686 |
| P932 | PMC publication ID | 20785 |
| P698 | PubMed publication ID | 9114052 |
| P5875 | ResearchGate publication ID | 14104217 |
| P2093 | author name string | A Aruffo | |
| H D Ochs | |||
| M A Kay | |||
| C B Wilson | |||
| D Hollenbaugh | |||
| A M Gown | |||
| P Linsley | |||
| L Meuse | |||
| P2860 | cites work | Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation | Q24311763 |
| A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells | Q28187669 | ||
| The role of the CD28 receptor during T cell responses to antigen | Q28263234 | ||
| Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 | Q28284177 | ||
| The CD40 antigen and its ligand | Q28286277 | ||
| Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand | Q34367466 | ||
| Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression | Q34615481 | ||
| In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs | Q35109095 | ||
| Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy | Q35232341 | ||
| Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver | Q35559973 | ||
| Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses | Q35837026 | ||
| Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues | Q35868592 | ||
| Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo | Q35874197 | ||
| B70 antigen is a second ligand for CTLA-4 and CD28 | Q36697598 | ||
| New perspectives of CD28-B7-mediated T cell costimulation | Q40401948 | ||
| Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors | Q40942254 | ||
| CD40 and its ligand in host defense | Q40986859 | ||
| Immune regulation by CD40 and its ligand GP39. | Q41039754 | ||
| FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer | Q41275978 | ||
| MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. | Q41664847 | ||
| Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production | Q41853080 | ||
| Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion | Q42941965 | ||
| Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. | Q43535009 | ||
| Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration | Q45866667 | ||
| Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. | Q45868863 | ||
| Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo | Q45879004 | ||
| Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis | Q48913563 | ||
| Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways | Q56908985 | ||
| Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4 | Q56909392 | ||
| Induction and reversal of long-lived specific unresponsiveness to a T-dependent antigen following CTLA4Ig treatment | Q56909426 | ||
| Identification of an Alternative CTLA-4 Ligand Costimulatory for T Cell Activation | Q56909813 | ||
| Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg | Q56909899 | ||
| Therapeutic serum concentrations of human alpha-1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes | Q64383253 | ||
| Strain-dependent leakiness of mice with severe combined immune deficiency | Q70661007 | ||
| The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome | Q72068543 | ||
| Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40 | Q72093299 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| Adenoviridae | Q193447 | ||
| P304 | page(s) | 4686-4691 | |
| P577 | publication date | 1997-04-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver | |
| P478 | volume | 94 |
| Q33841039 | "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung |
| Q45858715 | A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model |
| Q43709939 | A non-immunogenic adenoviral vector, coexpressing CTLA4Ig and bilirubin-uridine-diphosphoglucuronateglucuronosyltransferase permits long-term, repeatable transgene expression in the Gunn rat model of Crigler-Najjar syndrome |
| Q44813160 | AAV gene transfer to the retina does not protect retrovirally transduced hepatocytes from the immune response |
| Q34497332 | AAV-mediated gene transfer for hemophilia |
| Q40015350 | Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo |
| Q41732556 | Adenoviral gene transfer is inhibited by soluble factors in malignant pleural effusions |
| Q41628950 | Adenoviral vectors for gene transfer |
| Q90122264 | Adenovirus Biodistribution is Modified in Sensitive Animals Compared to Naïve Animals |
| Q33818043 | Adenovirus-mediated gene expression in vivo is enhanced by the antiapoptotic bcl-2 gene |
| Q64379583 | Blocking B7 and CD40 co-stimulatory molecules decreases antiviral T cell activity |
| Q44990105 | CTLA4Ig delivered by high-capacity adenoviral vector induces stable expression of dystrophin in mdx mouse muscle |
| Q38820937 | Cardiac gene therapy: are we there yet? |
| Q74356870 | Carrier-mediated enhancement of cognate T cell help: the basis for enhanced immunogenicity of meningococcal outer membrane protein polysaccharide conjugate vaccine |
| Q33243196 | Co-expression of sCD40LIg and CTLA4Ig mediated by adenovirus prolonged mouse skin allograft survival |
| Q33783905 | Combinatorial blockade of calcineurin and CD28 signaling facilitates primary and secondary therapeutic gene transfer by adenovirus vectors in dystrophic (mdx) mouse muscles |
| Q35804801 | Differential targeting of feline photoreceptors by recombinant adeno-associated viral vectors: implications for preclinical gene therapy trials. |
| Q41994111 | Effect of immunomodulation with anti-CD40L antibody on adenoviral-mediated transgene expression in mouse anterior segment |
| Q40890776 | Efficient adenoviral gene transfer to kidney cortical vasculature utilizing a fiber modified vector |
| Q33643006 | Engineering viral vectors to subvert the airway defense response |
| Q39589248 | Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure |
| Q34313075 | Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. |
| Q34000001 | Existing antilisterial immunity does not inhibit the development of a Listeria monocytogenes-specific primary cytotoxic T-lymphocyte response. |
| Q33804205 | Expression of herpes simplex virus ICP47 and human cytomegalovirus US11 prevents recognition of transgene products by CD8(+) cytotoxic T lymphocytes |
| Q73939993 | Gene therapy |
| Q64376611 | Gene therapy for cystic fibrosis |
| Q35884548 | Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies |
| Q45856156 | Gene therapy for inherited neurological disorders: towards therapeutic intervention in the Lesch-Nyhan syndrome. |
| Q39511773 | Gene therapy for lung cancer malignant pleural effusion: current and future nano-biotechnology |
| Q34385774 | Gene therapy: future therapies in osteoarthritis. |
| Q28277560 | Gutless adenovirus: last-generation adenovirus for gene therapy |
| Q39459253 | HIV-1 vaccine-specific responses induced by Listeria vector vaccines are maintained in mice subsequently infected with a model helminth parasite, Schistosoma mansoni. |
| Q33869825 | Hepatitis C virus core and envelope proteins do not suppress the host's ability to clear a hepatic viral infection |
| Q64380983 | Humoral immune responses to adenovirus vectors in the brain |
| Q35749783 | Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion. |
| Q35131229 | Immune responses to adeno-associated virus and its recombinant vectors |
| Q35131227 | Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy |
| Q35849770 | Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice |
| Q33813779 | Implication of interfering antibody formation and apoptosis as two different mechanisms leading to variable duration of adenovirus-mediated transgene expression in immune-competent mice |
| Q40859645 | Improvement of multiple pathophysiological phenotypes of klotho (kl/kl) mice by adenovirus-mediated expression of the klotho gene |
| Q37945219 | Improving adenovirus based gene transfer: strategies to accomplish immune evasion |
| Q37394036 | In vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors |
| Q38332622 | Inhibition of NF-kappaB activation in combination with bcl-2 expression allows for persistence of first-generation adenovirus vectors in the mouse liver |
| Q45871871 | Inhibition of costimulation allows for repeated systemic administration of adenoviral vector in rhesus monkeys. |
| Q64379968 | Insertion of CTCF-binding sites into a first-generation adenovirus vector reduces the innate inflammatory response and prolongs transgene expression |
| Q35904443 | Liver gene therapy: advances and hurdles |
| Q28085748 | Liver-targeted gene therapy: Approaches and challenges |
| Q45862119 | Macrophage inflammatory protein-2 gene therapy attenuates adenovirus- and acetaminophen-mediated hepatic injury |
| Q38022486 | Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review. |
| Q34269646 | Molecular therapeutics of liver disease |
| Q34746476 | Oral adenoviral-based vaccines: historical perspective and future opportunity |
| Q45887065 | Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses |
| Q33817933 | Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo |
| Q24635276 | PEGylated Adenoviruses: From Mice to Monkeys |
| Q34860648 | Parenchymal expression of CD40 exacerbates adenovirus-induced hepatitis in mice. |
| Q39590288 | Readministration of adenovirus vector in nonhuman primate lungs by blockade of CD40-CD40 ligand interactions |
| Q45855508 | Readministration of helper-dependent adenovirus to mouse lung |
| Q33835246 | Role of CD28/CD80-86 and CD40/CD154 costimulatory interactions in host defense to primary herpes simplex virus infection |
| Q34807096 | Strategies for muscle-specific targeting of adenoviral gene transfer vectors |
| Q33713999 | Strategies to modulate immune responses: a new frontier for gene therapy |
| Q39601191 | Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors |
| Q33786029 | Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure |
| Q39459260 | Successful vaccination of immune suppressed recipients using Listeria vector HIV-1 vaccines in helminth infected mice |
| Q64379313 | Sustained muscle expression of dystrophin from a high-capacity adenoviral vector with systemic gene transfer of T cell costimulatory blockade |
| Q33645370 | Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice |
| Q30764037 | The T-cell-dependent antibody response assay in nonclinical studies of pharmaceuticals and chemicals: study design, data analysis, interpretation |
| Q34079562 | Tissue engineering via local gene delivery: update and future prospects for enhancing the technology |
| Q45885438 | Transient blocking of both B7.1 (CD80) and B7.2 (CD86) in addition to CD40-CD40L interaction fully abrogates the immune response following systemic injection of adenovirus vector |
| Q45862517 | Transient cyclophosphamide treatment before intraportal readministration of an adenoviral vector can induce re-expression of the original gene construct in rat liver |
| Q42223027 | Transient depletion of specific immune cell populations to improve adenovirus-mediated transgene expression in the liver |
| Q33783991 | Transient inhibition of CD28 and CD40 ligand interactions prolongs adenovirus-mediated transgene expression in the lung and facilitates expression after secondary vector administration |
| Q35847178 | Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances |
Search more.